Medpace Holdings Inc. (MEDP): Bares Capital Trims Stake

Why It Matters

The stake reduction signals Bares Capital’s reassessment of Medpulse’s growth trajectory amid a competitive CRO landscape, and highlights the firm’s high margins and aggressive buyback strategy as key valuation drivers for investors.

Key Takeaways

• Bares Capital cut Medpace stake by ~30% in Q3 2025
• Medpace's Q1 2026 backlog conversion rose to 23.3%
• Revenue grew 26.5% while headcount increased 5.7% YoY
• Share buybacks rose to $912.9M in 2025, from $174M
• Medpace margins exceed those of larger CRO peers

Pulse Analysis

Bares Capital’s recent filing reveals a strategic pivot away from Medpace Holdings after a dramatic 300% stake increase earlier in 2025. The fund’s exposure fell from roughly 157,000 shares to 111,000, a 30% decline, suggesting a recalibration of risk or a reallocation toward sectors perceived as higher growth. For investors tracking institutional moves, the timing aligns with broader market rotation toward technology and AI themes, where capital is flowing faster than into traditional contract research organizations.

Medpace’s operational metrics reinforce why the CRO remains attractive despite the fund’s pullback. The company posted a 23.3% backlog conversion rate in Q1 2026, indicating efficient project execution and a healthy pipeline of clinical trials. More striking is the revenue‑to‑headcount ratio: a 26.5% revenue surge contrasted with a modest 5.7% increase in staff, delivering a productivity premium that outpaces larger peers. Coupled with higher-than‑average profit margins, these figures position Medpace as a levered play for investors seeking exposure to the drug development value chain without the cost pressures that have hampered other CROs.

The firm’s capital return strategy adds another layer of appeal. In 2025, Medpace accelerated share repurchases to $912.9 million, up from $174 million the year before, signaling confidence in cash flow generation and a commitment to shareholder value. While some analysts argue AI‑centric stocks may offer steeper upside, Medpace’s blend of robust margins, efficient growth, and generous buybacks provides a defensive yet upside‑potential profile, especially for portfolios looking to balance high‑growth bets with stable, cash‑rich enterprises.